Titre :

External validation of the dynpg for kidney transplant recipients

Auteur(s) :

Lenain, Remi [Auteur]
Service de Néphrologie et Transplantation rénale [CHRU-lille]
Dantan, Etienne [Auteur]
MethodS in Patients-centered outcomes and HEalth ResEarch [SPHERE]
Giral, Magali [Auteur]
Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology [U1064 Inserm - CR2TI]
CIC biothérapies CBT 0503 [Nantes]
Foucher, Yohann [Auteur]
MethodS in Patients-centered outcomes and HEalth ResEarch [SPHERE]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Asar, Ozgur [Auteur]
Acibadem University
Naesens, Maarten [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
University Hospitals Leuven [Leuven]
Hazzan, Marc [Auteur]
Service de Néphrologie et Transplantation rénale [CHRU-lille]
Fournier, Marie-Cecile [Auteur]
MethodS in Patients-centered outcomes and HEalth ResEarch [SPHERE]

Titre de la revue :

Transplantation

Nom court de la revue :

Transplantation

Date de publication :

2020-02-27

ISSN :

1534-6080

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

In kidney transplantation, dynamic prediction of patient and kidney graft survival (DynPG) may help to promote therapeutic alliance by delivering personalized evidence-based information about long-term graft survival for ...
Lire la suite >In kidney transplantation, dynamic prediction of patient and kidney graft survival (DynPG) may help to promote therapeutic alliance by delivering personalized evidence-based information about long-term graft survival for kidney transplant recipients. The objective of the current study is to externally validate the DynPG. Based on 6 baseline variables, the DynPG can be updated with any new serum creatinine measure available during the follow-up. From an external validation sample of 1637 kidney recipients with a functioning graft at 1-year posttransplantation from 2 European transplantation centers, we assessed the prognostic performance of the DynPG. As one can expect from an external validation sample, differences in several recipient, donor, and transplantation characteristics compared with the learning sample were observed. Patients were mainly transplanted from deceased donors (91.6% versus 84.8%; P < 0.01), were less immunized against HLA class I (18.4% versus 32.7%; P < 0.01) and presented less comorbidities (62.2% for hypertension versus 82.7%, P < 0.01; 25.1% for cardiovascular disease versus 33.9%, P < 0.01). Despite these noteworthy differences, the area under the ROC curve varied from 0.70 (95% confidence interval [CI], 0.64-0.76) to 0.76 (95% CI, 0.64-0.88) for prediction times at 1 and 6 years posttransplantation respectively, and calibration plots revealed reasonably accurate predictions. We validated the prognostic capacities of the DynPG in terms of both discrimination and calibration. Our study showed the robustness of the DynPG for informing both the patient and the physician, and its transportability for a cohort presenting different features than the one used for the DynPG development.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:32Z
2024-02-01T14:48:17Z